Antengene Corporation, a biopharmaceutical company dedicated to developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, and WuXi Biologics have signed a strategic cooperation Memorandum of Understanding (MoU) to collaborate on the development and production of novel drugs, and jointly promote the R&D of innovative oncology therapies.   China’s cancer incidence and mortality have been increasing in recent years. Low rates of survival...